According to Stratistics MRC, the Global Cancer Vaccines market is accounted for $2.25 billion in 2015 and is expected to reach $10.00 billion by 2022 growing at a CAGR of 23.7%. Factors such as rising number of cancer patients, increasing ageing population and awareness of vaccines are fueling the market. However, less availability of vaccines and advanced treatments in underdeveloped regions may limit the market growth.
North America accounted for the largest share in the market followed by Asia Pacific. The favourable growth is attributed to supportive government and other organisations such as World health organisation and GAVI initiatives.
Some of the key players in Global Cancer Vaccines market include Oxford BioMedica, Vaccinogen Inc., GlaxoSmithKline, Sanofi India Limited-P.P. Enterprises, Juvaris Biotherapeutics, Merk&co, Prima BioMed Ltd, Cytos Biotechnology AG, Ubivac, duro BioTech, AstraZeneca plc., and MedImmune, LLC.
Disease Indication Covered:
• Cervical cancer
• Esophageal cancer
• Liver cancer
• Prostate cancer
• Lung cancer
• Breast cancer
• Stomach cancer
Technologies Covered:
• Inactivated Vaccines
• Peptide/protein vaccines
• Synthetic Vaccines
• Toxoid Vaccines
• Live Attenuated Vaccines
• Recombinant Vector Vaccines
• Antigen vaccines
• Dendritic Cell Vaccines
• Subunit Vaccines
• Heat shock protein vaccines
• DNA- and vector-based vaccines
• Conjugate Vaccines
• Anti-idiotype vaccines
• Cancer stem cell vaccines
End Users Covered:
• Adults
• Paediatrics
Vaccine Types Covered:
• Therapeutic Vaccines
• Preventive Vaccines
Regions Covered:
• North America
o US
o Canada
o Mexico
• Europe
o Germany
o France
o Italy
o UK
o Spain
o Rest of Europe
• Asia Pacific
o Japan
o China
o India
o Australia
o New Zealand
o Rest of Asia Pacific
• Rest of the World
o Middle East
o Brazil
o Argentina
o South Africa
o Egypt
What our report offers:
- Market share assessments for the regional and country level segments
- Market share analysis of the top industry players
- Strategic recommendations for the new entrants
- Market forecasts for a minimum of 7 years of all the mentioned segments, sub segments and the regional markets
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements
1 Executive Summary
2 Preface
2.1 Abstract
2.2 Stake Holders
2.3 Research Scope
2.4 Research Methodology
2.4.1 Data Mining
2.4.2 Data Analysis
2.4.3 Data Validation
2.4.4 Research Approach
2.5 Research Sources
2.5.1 Primary Research Sources
2.5.2 Secondary Research Sources
2.5.3 Assumptions
3 Market Trend Analysis
3.1 Introduction
3.2 Drivers
3.3 Restraints
3.4 Opportunities
3.5 Threats
3.6 Technology Analysis
3.7 End User Analysis
3.8 Emerging Markets
4 Porters Five Force Analysis
4.1 Bargaining power of suppliers
4.2 Bargaining power of buyers
4.3 Threat of substitutes
4.4 Threat of new entrants
4.5 Competitive rivalry
5 Global Cancer Vaccines Market, By Disease Indication
5.1 Introduction
5.2 Cervical cancer
5.3 Esophageal cancer
5.4 Liver cancer
5.5 Prostate cancer
5.6 Lung cancer
5.7 Breast cancer
5.8 Stomach cancer
6 Global Cancer Vaccines Market, By Technology
6.1 Introduction
6.2 Inactivated Vaccines
6.3 Peptide/protein vaccines
6.4 Synthetic Vaccines
6.5 Toxoid Vaccines
6.6 Live Attenuated Vaccines
6.7 Recombinant Vector Vaccines
6.8 Antigen vaccines
6.9 Dendritic Cell Vaccines
6.10 Subunit Vaccines
6.11 Heat shock protein vaccines
6.12 DNA- and vector-based vaccines
6.13 Conjugate Vaccines
6.14 Anti-idiotype vaccines
6.15 Cancer stem cell vaccines
7 Global Cancer Vaccines Market, By End User
7.1 Introduction
7.2 Adults
7.3 Pediatrics
8 Global Cancer Vaccines Market, By Vaccine Type
8.1 Therapeutic Vaccines
8.2 Preventive Vaccines
9 Global Cancer Vaccines Market, By Geography
9.1 North America
9.1.1 US
9.1.2 Canada
9.1.3 Mexico
9.2 Europe
9.2.1 Germany
9.2.2 France
9.2.3 Italy
9.2.4 UK
9.2.5 Spain
9.2.6 Rest of Europe
9.3 Asia Pacific
9.3.1 Japan
9.3.2 China
9.3.3 India
9.3.4 Australia
9.3.5 New Zealand
9.3.6 Rest of Asia Pacific
9.4 Rest of the World
9.4.1 Middle East
9.4.2 Brazil
9.4.3 Argentina
9.4.4 South Africa
9.4.5 Egypt
10 Key Developments
10.1 Agreements, Partnerships, Collaborations and Joint Ventures
10.2 Acquisitions & Mergers
10.3 New Product Launch
10.4 Expansions
10.5 Other Key Strategies
11 Company Profiling
11.1 Oxford BioMedica
11.2 Vaccinogen Inc.
11.3 GlaxoSmithKline
11.4 Sanofi India Limited-P.P. Enterprises
11.5 Juvaris Biotherapeutics
11.6 Merk&co
11.7 Prima BioMed Ltd
11.8 Cytos Biotechnology AG
11.9 Ubivac
11.10 duro BioTech
11.11 AstraZeneca plc
11.12 MedImmune, LLC
11.13 Nova Rx Corporation
11.14 Argos Therapeutics
11.15 Prima BioMed Ltd
List of Tables
1 Global Cancer Vaccines Market Outlook, By Region (2013-2022) ($MN)
2 Global Cancer Vaccines Market Outlook, By Disease Indication (2013-2022) ($MN)
3 Global Cancer Vaccines Market Outlook, By Cervical cancer (2013-2022) ($MN)
4 Global Cancer Vaccines Market Outlook, By Esophageal cancer (2013-2022) ($MN)
5 Global Cancer Vaccines Market Outlook, By Liver cancer (2013-2022) ($MN)
6 Global Cancer Vaccines Market Outlook, By Prostate cancer (2013-2022) ($MN)
7 Global Cancer Vaccines Market Outlook, By Lung cancer (2013-2022) ($MN)
8 Global Cancer Vaccines Market Outlook, By Breast cancer (2013-2022) ($MN)
9 Global Cancer Vaccines Market Outlook, By Stomach cancer (2013-2022) ($MN)
10 Global Cancer Vaccines Market Outlook, By Technology (2013-2022) ($MN)
11 Global Cancer Vaccines Market Outlook, By Inactivated Vaccines (2013-2022) ($MN)
12 Global Cancer Vaccines Market Outlook, By Peptide/protein vaccines (2013-2022) ($MN)
13 Global Cancer Vaccines Market Outlook, By Synthetic Vaccines (2013-2022) ($MN)
14 Global Cancer Vaccines Market Outlook, By Toxoid Vaccine (2013-2022) ($MN)
15 Global Cancer Vaccines Market Outlook, By Live Attenuated Vaccines (2013-2022) ($MN)
16 Global Cancer Vaccines Market Outlook, By Recombinant Vector Vaccines (2013-2022) ($MN)
17 Global Cancer Vaccines Market Outlook, By Antigen vaccines(2013-2022) ($MN)
18 Global Cancer Vaccines Market Outlook, By Dendritic Cell Vaccines (2013-2022) ($MN)
19 Global Cancer Vaccines Market Outlook, By Subunit Vaccines (2013-2022) ($MN)
20 Global Cancer Vaccines Market Outlook, By Heat shock protein vaccines (2013-2022) ($MN)
21 Global Cancer Vaccines Market Outlook, By DNA- and vector-based vaccines (2013-2022) ($MN)
22 Global Cancer Vaccines Market Outlook, By Conjugate Vaccines (2013-2022) ($MN)
23 Global Cancer Vaccines Market Outlook, By Anti-idiotype vaccines (2013-2022) ($MN)
24 Global Cancer Vaccines Market Outlook, By Cancer stem cell vaccines (2013-2022) ($MN)
25 Global Cancer Vaccines Market Outlook, By End User (2013-2022) ($MN)
26 Global Cancer Vaccines Market Outlook, By Adults (2013-2022) ($MN)
27 Global Cancer Vaccines Market Outlook, By Pediatrics (2013-2022) ($MN)
28 Global Cancer Vaccines Market Outlook, By Vaccine Type (2013-2022) ($MN)
29 Global Cancer Vaccines Market Outlook, By Therapeutic Vaccines (2013-2022) ($MN)
30 Global Cancer Vaccines Market Outlook, By Preventive Vaccines (2013-2022) ($MN)
31 Global Cancer Vaccines Market Outlook, By Adults (2013-2022) ($MN)
32 North America Cancer Vaccines Market Outlook, By Country (2013-2022) ($MN)
33 North America Cancer Vaccines Market Outlook, By Disease Indication (2013-2022) ($MN)
34 North America Cancer Vaccines Market Outlook, By Cervical cancer (2013-2022) ($MN)
35 North America Cancer Vaccines Market Outlook, By Esophageal cancer (2013-2022) ($MN)
36 North America Cancer Vaccines Market Outlook, By Liver cancer (2013-2022) ($MN)
37 North America Cancer Vaccines Market Outlook, By Prostate cancer (2013-2022) ($MN)
38 North America Cancer Vaccines Market Outlook, By Lung cancer (2013-2022) ($MN)
39 North America Cancer Vaccines Market Outlook, By Breast cancer (2013-2022) ($MN)
40 North America Cancer Vaccines Market Outlook, By Stomach cancer (2013-2022) ($MN)
41 North America Cancer Vaccines Market Outlook, By Technology (2013-2022) ($MN)
42 North America Cancer Vaccines Market Outlook, By Inactivated Vaccines (2013-2022) ($MN)
43 North America Cancer Vaccines Market Outlook, By Peptide/protein vaccines (2013-2022) ($MN)
44 North America Cancer Vaccines Market Outlook, By Synthetic Vaccines (2013-2022) ($MN)
45 North America Cancer Vaccines Market Outlook, By Toxoid Vaccine (2013-2022) ($MN)
46 North America Cancer Vaccines Market Outlook, By Live Attenuated Vaccines (2013-2022) ($MN)
47 North America Cancer Vaccines Market Outlook, By Recombinant Vector Vaccines (2013-2022) ($MN)
48 North America Cancer Vaccines Market Outlook, By Antigen vaccines(2013-2022) ($MN)
49 North America Cancer Vaccines Market Outlook, By Dendritic Cell Vaccines (2013-2022) ($MN)
50 North America Cancer Vaccines Market Outlook, By Subunit Vaccines (2013-2022) ($MN)
51 North America Cancer Vaccines Market Outlook, By Heat shock protein vaccines (2013-2022) ($MN)
52 North America Cancer Vaccines Market Outlook, By DNA- and vector-based vaccines (2013-2022) ($MN)
53 North America Cancer Vaccines Market Outlook, By Conjugate Vaccines (2013-2022) ($MN)
54 North America Cancer Vaccines Market Outlook, By Anti-idiotype vaccines (2013-2022) ($MN)
55 North America Cancer Vaccines Market Outlook, By Cancer stem cell vaccines (2013-2022) ($MN)
56 North America Cancer Vaccines Market Outlook, By End User (2013-2022) ($MN)
57 North America Cancer Vaccines Market Outlook, By Adults (2013-2022) ($MN)
58 North America Cancer Vaccines Market Outlook, By Pediatrics (2013-2022) ($MN)
59 North America Cancer Vaccines Market Outlook, By Vaccine Type (2013-2022) ($MN)
60 North America Cancer Vaccines Market Outlook, By Therapeutic Vaccines (2013-2022) ($MN)
61 North America Cancer Vaccines Market Outlook, By Preventive Vaccines (2013-2022) ($MN)
62 North America Cancer Vaccines Market Outlook, By Adults (2013-2022) ($MN)
63 Europe Cancer Vaccines Market Outlook, By Country (2013-2022) ($MN)
64 Europe Cancer Vaccines Market Outlook, By Disease Indication (2013-2022) ($MN)
65 Europe Cancer Vaccines Market Outlook, By Cervical cancer (2013-2022) ($MN)
66 Europe Cancer Vaccines Market Outlook, By Esophageal cancer (2013-2022) ($MN)
67 Europe Cancer Vaccines Market Outlook, By Liver cancer (2013-2022) ($MN)
68 Europe Cancer Vaccines Market Outlook, By Prostate cancer (2013-2022) ($MN)
69 Europe Cancer Vaccines Market Outlook, By Lung cancer (2013-2022) ($MN)
70 Europe Cancer Vaccines Market Outlook, By Breast cancer (2013-2022) ($MN)
71 Europe Cancer Vaccines Market Outlook, By Stomach cancer (2013-2022) ($MN)
72 Europe Cancer Vaccines Market Outlook, By Technology (2013-2022) ($MN)
73 Europe Cancer Vaccines Market Outlook, By Inactivated Vaccines (2013-2022) ($MN)
74 Europe Cancer Vaccines Market Outlook, By Peptide/protein vaccines (2013-2022) ($MN)
75 Europe Cancer Vaccines Market Outlook, By Synthetic Vaccines (2013-2022) ($MN)
76 Europe Cancer Vaccines Market Outlook, By Toxoid Vaccine (2013-2022) ($MN)
77 Europe Cancer Vaccines Market Outlook, By Live Attenuated Vaccines (2013-2022) ($MN)
78 Europe Cancer Vaccines Market Outlook, By Recombinant Vector Vaccines (2013-2022) ($MN)
79 Europe Cancer Vaccines Market Outlook, By Antigen vaccines(2013-2022) ($MN)
80 Europe Cancer Vaccines Market Outlook, By Dendritic Cell Vaccines (2013-2022) ($MN)
81 Europe Cancer Vaccines Market Outlook, By Subunit Vaccines (2013-2022) ($MN)
82 Europe Cancer Vaccines Market Outlook, By Heat shock protein vaccines (2013-2022) ($MN)
83 Europe Cancer Vaccines Market Outlook, By DNA- and vector-based vaccines (2013-2022) ($MN)
84 Europe Cancer Vaccines Market Outlook, By Conjugate Vaccines (2013-2022) ($MN)
85 Europe Cancer Vaccines Market Outlook, By Anti-idiotype vaccines (2013-2022) ($MN)
86 Europe Cancer Vaccines Market Outlook, By Cancer stem cell vaccines (2013-2022) ($MN)
87 Europe Cancer Vaccines Market Outlook, By End User (2013-2022) ($MN)
88 Europe Cancer Vaccines Market Outlook, By Adults (2013-2022) ($MN)
89 Europe Cancer Vaccines Market Outlook, By Pediatrics (2013-2022) ($MN)
90 Europe Cancer Vaccines Market Outlook, By Vaccine Type (2013-2022) ($MN)
91 Europe Cancer Vaccines Market Outlook, By Therapeutic Vaccines (2013-2022) ($MN)
92 Europe Cancer Vaccines Market Outlook, By Preventive Vaccines (2013-2022) ($MN)
93 Europe Cancer Vaccines Market Outlook, By Adults (2013-2022) ($MN)
94 Asia Pacific Cancer Vaccines Market Outlook, By Country (2013-2022) ($MN)
95 Asia Pacific Cancer Vaccines Market Outlook, By Disease Indication (2013-2022) ($MN)
96 Asia Pacific Cancer Vaccines Market Outlook, By Cervical cancer (2013-2022) ($MN)
97 Asia Pacific Cancer Vaccines Market Outlook, By Esophageal cancer (2013-2022) ($MN)
98 Asia Pacific Cancer Vaccines Market Outlook, By Liver cancer (2013-2022) ($MN)
99 Asia Pacific Cancer Vaccines Market Outlook, By Prostate cancer (2013-2022) ($MN)
100 Asia Pacific Cancer Vaccines Market Outlook, By Lung cancer (2013-2022) ($MN)
101 Asia Pacific Cancer Vaccines Market Outlook, By Breast cancer (2013-2022) ($MN)
102 Asia Pacific Cancer Vaccines Market Outlook, By Stomach cancer (2013-2022) ($MN)
103 Asia Pacific Cancer Vaccines Market Outlook, By Technology (2013-2022) ($MN)
104 Asia Pacific Cancer Vaccines Market Outlook, By Inactivated Vaccines (2013-2022) ($MN)
105 Asia Pacific Cancer Vaccines Market Outlook, By Peptide/protein vaccines (2013-2022) ($MN)
106 Asia Pacific Cancer Vaccines Market Outlook, By Synthetic Vaccines (2013-2022) ($MN)
107 Asia Pacific Cancer Vaccines Market Outlook, By Toxoid Vaccine (2013-2022) ($MN)
108 Asia Pacific Cancer Vaccines Market Outlook, By Live Attenuated Vaccines (2013-2022) ($MN)
109 Asia Pacific Cancer Vaccines Market Outlook, By Recombinant Vector Vaccines (2013-2022) ($MN)
110 Asia Pacific Cancer Vaccines Market Outlook, By Antigen vaccines(2013-2022) ($MN)
111 Asia Pacific Cancer Vaccines Market Outlook, By Dendritic Cell Vaccines (2013-2022) ($MN)
112 Asia Pacific Cancer Vaccines Market Outlook, By Subunit Vaccines (2013-2022) ($MN)
113 Asia Pacific Cancer Vaccines Market Outlook, By Heat shock protein vaccines (2013-2022) ($MN)
114 Asia Pacific Cancer Vaccines Market Outlook, By DNA- and vector-based vaccines (2013-2022) ($MN)
115 Asia Pacific Cancer Vaccines Market Outlook, By Conjugate Vaccines (2013-2022) ($MN)
116 Asia Pacific Cancer Vaccines Market Outlook, By Anti-idiotype vaccines (2013-2022) ($MN)
117 Asia Pacific Cancer Vaccines Market Outlook, By Cancer stem cell vaccines (2013-2022) ($MN)
118 Asia Pacific Cancer Vaccines Market Outlook, By End User (2013-2022) ($MN)
119 Asia Pacific Cancer Vaccines Market Outlook, By Adults (2013-2022) ($MN)
120 Asia Pacific Cancer Vaccines Market Outlook, By Pediatrics (2013-2022) ($MN)
121 Asia Pacific Cancer Vaccines Market Outlook, By Vaccine Type (2013-2022) ($MN)
122 Asia Pacific Cancer Vaccines Market Outlook, By Therapeutic Vaccines (2013-2022) ($MN)
123 Asia Pacific Cancer Vaccines Market Outlook, By Preventive Vaccines (2013-2022) ($MN)
124 Asia Pacific Cancer Vaccines Market Outlook, By Adults (2013-2022) ($MN)
125 RoW Cancer Vaccines Market Outlook, By Country (2013-2022) ($MN)
126 RoW Cancer Vaccines Market Outlook, By Disease Indication (2013-2022) ($MN)
127 RoW Cancer Vaccines Market Outlook, By Cervical cancer (2013-2022) ($MN)
128 RoW Cancer Vaccines Market Outlook, By Esophageal cancer (2013-2022) ($MN)
129 RoW Cancer Vaccines Market Outlook, By Liver cancer (2013-2022) ($MN)
130 RoW Cancer Vaccines Market Outlook, By Prostate cancer (2013-2022) ($MN)
131 RoW Cancer Vaccines Market Outlook, By Lung cancer (2013-2022) ($MN)
132 RoW Cancer Vaccines Market Outlook, By Breast cancer (2013-2022) ($MN)
133 RoW Cancer Vaccines Market Outlook, By Stomach cancer (2013-2022) ($MN)
134 RoW Cancer Vaccines Market Outlook, By Technology (2013-2022) ($MN)
135 RoW Cancer Vaccines Market Outlook, By Inactivated Vaccines (2013-2022) ($MN)
136 RoW Cancer Vaccines Market Outlook, By Peptide/protein vaccines (2013-2022) ($MN)
137 RoW Cancer Vaccines Market Outlook, By Synthetic Vaccines (2013-2022) ($MN)
138 RoW Cancer Vaccines Market Outlook, By Toxoid Vaccine (2013-2022) ($MN)
139 RoW Cancer Vaccines Market Outlook, By Live Attenuated Vaccines (2013-2022) ($MN)
140 RoW Cancer Vaccines Market Outlook, By Recombinant Vector Vaccines (2013-2022) ($MN)
141 RoW Cancer Vaccines Market Outlook, By Antigen vaccines(2013-2022) ($MN)
142 RoW Cancer Vaccines Market Outlook, By Dendritic Cell Vaccines (2013-2022) ($MN)
143 RoW Cancer Vaccines Market Outlook, By Subunit Vaccines (2013-2022) ($MN)
144 RoW Cancer Vaccines Market Outlook, By Heat shock protein vaccines (2013-2022) ($MN)
145 RoW Cancer Vaccines Market Outlook, By DNA- and vector-based vaccines (2013-2022) ($MN)
146 RoW Cancer Vaccines Market Outlook, By Conjugate Vaccines (2013-2022) ($MN)
147 RoW Cancer Vaccines Market Outlook, By Anti-idiotype vaccines (2013-2022) ($MN)
148 RoW Cancer Vaccines Market Outlook, By Cancer stem cell vaccines (2013-2022) ($MN)
149 RoW Cancer Vaccines Market Outlook, By End User (2013-2022) ($MN)
150 RoW Cancer Vaccines Market Outlook, By Adults (2013-2022) ($MN)
151 RoW Cancer Vaccines Market Outlook, By Pediatrics (2013-2022) ($MN)
152 RoW Cancer Vaccines Market Outlook, By Vaccine Type (2013-2022) ($MN)
153 RoW Cancer Vaccines Market Outlook, By Therapeutic Vaccines (2013-2022) ($MN)
154 RoW Cancer Vaccines Market Outlook, By Preventive Vaccines (2013-2022) ($MN)
155 RoW Cancer Vaccines Market Outlook, By Adults (2013-2022) ($MN)
